Showing results (181-190 of 792) with videos related to

Sort By:
Pageof 80
Blood Advances|January 4, 2018
CD86 regulates myeloma cell survivalCatherine M Gavile, Benjamin G Barwick, Scott Newman, et al.
International Journal of Hematology|July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaAsher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
Leukemia & Lymphoma|October 31, 2006
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphomaSagar Lonial, Martha Arellano, Donald Hutcherson, et al.
The Oncologist|January 13, 2006
A practical update on the use of bortezomib in the management of multiple myelomaJesús San Miguel, Joan Bladé, Mario Boccadoro, et al.
Cancer|April 21, 2012
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemiaMartha Arellano, Suchita Pakkala, Amelia Langston, et al.
Cancer|May 16, 2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patientsAjay K Nooka, Nisha S Joseph, Jonathan L Kaufman, et al.
Cancer Medicine|April 28, 2016
Lack of health maintenance examinations and risk in myeloma patientsJoseph D Tariman, Charise Gleason, Beth Faiman, et al.
Clinical and Experimental Nephrology|February 22, 2008
Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemiaAisha Shaikh, Thomas M Habermann, Mary E Fidler, et al.
Blood Advances|January 26, 2021
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myelomaShaji Kumar, Alan Fu, Ruben Niesvizky, et al.
Mayo Clinic Proceedings|March 4, 2014
Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosisSameer A Parikh, Prashant Kapoor, Louis Letendre, et al.
Pageof 80